Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 4/20 | 0.53 |
| ▸ | PPARG | P37231 | 2/20 | 0.53 |
| ▸ | PPARD | Q03181 | 1/20 | 0.53 |
| ▸ | PPARA | Q07869 | 1/20 | 0.53 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.52 |
| ▸ | SERPINE1 | P05121 | 3/20 | 0.52 |
| ▸ | DHODH | Q02127 | 2/20 | 0.50 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.50 |
| ▸ | PTGER4 | P35408 | 4/20 | 0.49 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.49 |
| ▸ | IGF2BP2 | Q9Y6M1 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.48 |
| ▸ | LTC4S | Q16873 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lithium Ion SCHEMBL7038945 | 0.89 | NR1H4 (0.48) | NR1H4PPARGPPARDPPARASERPINE1 | |
| SCHEMBL7038894 | 0.88 | PLAU (0.56) | NR1H4PPARGPPARDPPARASIRT2 | |
| SCHEMBL7038142 | 0.82 | IGF2BP2 (0.54) | NR1H4PPARGPPARDPPARAACMSD | |
| SCHEMBL7039689 | 0.81 | MAPT (0.55) | NR1H4PPARGPPARDPPARASERPINE1 | |
| SCHEMBL2273085 | 0.79 | ACLY (0.60) | ACMSDSERPINE1DHODHPTGER4SUCNR1 | |
| SCHEMBL7035247 | 0.79 | DHODH (0.51) | NR1H4PPARGPPARAACMSDSERPINE1 | |
| SCHEMBL22213632 | 0.78 | NPC1 (0.57) | NR1H4PPARGPPARDPPARADHODH | |
| SCHEMBL7038969 | 0.78 | DHODH (0.50) | NR1H4PPARGPPARAACMSDSERPINE1 | |
| SCHEMBL7237031 | 0.77 | SUCNR1 (0.73) | SERPINE1DHODHSIRT2KDM4ESUCNR1 | |
| SCHEMBL8044197 | 0.76 | DHODH (0.79) | NR1H4PPARGPPARDPPARADHODH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030073862-A1 | Compounds | BIOVITRUM AB (SE) | 2003-04-17 | — | — | US | claimed |
| US-20030073862-A1 | Compounds | BIOVITRUM AB (SE) | 2003-04-17 | — | — | US | disclosed |
| WO-2003004458-A1 | NEW COMPOUNDS | BIOVITRUM AB (SE) | 2003-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073862-A1 | Compounds | PPARG, PPARA, PPARD | NR1H4 62/4885PPARG 1/4885PPARD 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.